Poor awareness of the symptoms of one of the least understood forms of cancer among the public and healthcare professionals, compounded by a complex diagnostic pathway, is leading to a ‘perfect storm’ of delays to diagnosis that is devastating lives, a new report launched today reveals.
We are delighted to hear the National Institute for Health and Care Excellence (NICE) has announced today that the tumour agnostic drug entrectinib will be made available for use in England.
Millions of people shielding from coronavirus (COVID-19) will be advised they can spend more time outside their homes from Monday 6 July, the Health and Social Care Secretary has announced.
A new study part-funded by Sarcoma UK and published in the Lancet has revealed that developing a Covid-19 infection just before or after having surgery can have a major impact on survival – around half of patients with confirmed Covid-19 suffered lung complications after surgery and sadly, 38% of these people died.
To help understand why sarcoma seems resistant to immunotherapy, Sarcoma UK has committed to investing £250,000 to fund a major new project led by Prof. Beggs at the University of Birmingham,
Delays and changes to treatment as a result of the COVID-19 emergency in England could result in at least 20% more deaths over the next 12 months in peop
In recent weeks, we have been inundated with phone calls, emails and text messages around COVID-19 and what this means to sarcoma cancer patients who need to know what the ever-shifting circumstanc
